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Introduction
Epstein-Barr virus (EBV), after an initial lytic phase,
establishes a life-long latent infection in resting mem-
ory B cells (1). Despite a relatively benign course in
most carriers, EBV has growth-transforming capabili-
ties (2) and is associated with several malignancies, e.g.,
endemic Burkitt’s lymphoma, nasopharyngeal carci-
noma, and approximately half the cases of Hodgkin’s
lymphoma (3). It is important to identify mechanisms
whereby healthy carriers avoid development of EBV-
associated malignancy.
In most EBV-seropositive adults, strong CD8+ cyto-
toxic T-lymphocyte (CTL) responses develop (4). How-
ever, these are preferentially directed toward the
nuclear antigens, EBNA3A, EBNA3B, and EBNA3C (3,
5), which are not expressed in many EBV-associated
malignancies. EBV-transformed cells exhibit one of
three latency types distinguished from each other by
the panel of expressed EBV antigens (3). In latency I,
only EBNA1 is expressed, as in Burkitt’s lymphoma. In
latency II, exemplified by Hodgkin’s lymphoma and
nasopharyngeal carcinoma, LMP1 and LMP2, as well
as EBNA1, are expressed. Only in latency III
immunoblastic lymphomas are the highly immuno-
genic EBNA3 genes expressed. Therefore, many EBV-
associated malignancies do not seem to provide good
targets for the dominant human CD8+ T-cell response
to EBV-latency gene products.
The nuclear antigen, EBNA1, is an optimal EBV-
specific antigen because it must be expressed in all
proliferating EBV-infected cells to maintain the viral
episome. However, this protein contains an NH2-ter-
minal glycine-alanine repeat domain that blocks its
own proteosomal processing and hence presentation
on MHC class I molecules (6, 7). EBNA1-specific
CD8+ CTLs have been identified, but these do not
recognize EBV-transformed cells unless EBNA1 is
added externally (8). Likewise, CD8+ T cells specific
for LMP1 are infrequent and for LMP2 are observed
only in some haplotypes (4, 5, 9).
Therefore, to understand how most healthy carriers
of EBV avoid latency I and II malignancies, we turned
our attention to CD4+ T cells. In mouse models, these
T cells are important for resistance to cancer (10–12,
and reviewed in ref. 13) and viruses (14–17), including
virally induced malignancy (reviewed in refs. 13 and
18). Activated CD4+ T cells deliver survival and matu-
ration stimuli to dendritic cells (DCs), which, in turn,
are vital to the induction and expansion of antigen-spe-
cific CD8+ T lymphocytes (17, 19, 20). The type of acti-
vated CD4+ T cell also influences the outcome of the
immune response (reviewed in ref. 21). Th1 CD4+ cells
secrete IFN-γ and help in the development of cellular
immunity, including the activation of macrophages.
Th2 CD4+ cells secrete IL-4 and IL-5, thereby stimulat-
ing eosinophils and mucosal Ab production. Th1 CD4+
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dendritic cells infected with vaccinia vectors expressing EBNA1, 18 of 19 donors secreted IFN-γ,
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lished from six of six donors and IL-4 lines from three of six. Only the Th1 lines specifically lysed
targets expressing three different sources of EBNA1 protein. When the IgG isotype of EBNA1 plas-
ma Ab’s was tested, most specific Ab’s were IgG1 and of a high titer, confirming a Th1 response
to EBNA1 in vivo. Ab’s to other microbial antigens generally were not skewed toward IgG1. Given
emerging evidence that Th1 CD4+ T cells have several critical roles in host defense to viral infec-
tion and tumors, we propose that EBNA1-specific CD4+ Th1 cells contribute to resistance to EBV
and EBV-associated malignancies.
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T cells differ from TH2 cells in other ways, such as the
pattern of expressed chemokine receptors (22) and a
capacity to kill targets via Fas-FasL interactions
(reviewed in ref. 23).
Recently, we uncovered a consistent EBNA1-specif-
ic, CD4+ T-cell response in blood cells from healthy
donors (24). To detect these CD4+ T cells, a 2-week
stimulation culture was used in which DCs were the
antigen-presenting cells and purified CD4+ T cells
were the responders. The present study investigates
whether EBNA1-specific CD4+ T cells are polarized
toward a Th1 or Th2 phenotype and whether this
response can be detected ex vivo. We show that
EBNA1-specific CD4+ T cells are consistently Th1 and
that these cells can be directly isolated from blood.
Furthermore, EBNA1 Ab’s consistently are of the
opsonic and complement-fixing IgG1 subclass, reflect-
ing Th1 polarization in vivo. We discuss the emerging
evidence that Th1 cells are important for defense
against infection with persistent viruses and tumors.
Methods
Dendritic cell and CD4+ T-cell preparations. PBMCs were
obtained from leukocyte concentrates (New York
Blood Center, New York, New York, USA) and blood
from lab donors. After Ficoll-Hypaque (Amersham
Pharmacia Biotech, Uppsala, Sweden) centrifugation,
CD14+ cells were selected with monoclonal anti-CD14
conjugated to paramagnetic microbeads (Miltenyi
Biotec, Gladbach, Germany). Cells were passed
through an LS+/VS+ column attached to a MACS mag-
net (Miltenyi), washed three times with PBS contain-
ing 0.5% BSA (MACS buffer), and the column removed
from the magnet. MACS buffer was then flushed
through the column with a plunger to collect CD14+
cells. These were cultured at 2 × 106 per well in six-well
plates in medium (RPMI-1640 with 1% human serum,
glutamine, and gentamicin). rHuIL-4 (R&D Systems,
Minneapolis, Minnesota, USA) and rHuGM-CSF
(Immunex, Seattle, Washington, USA) were added
each to 1,000 U/ml on days 0, 2, 4, and 6. On day 6, the
nonadherent cells were transferred to a new six-well
plate, and half of the medium was replaced with
monocyte-conditioned medium for 2 days to mature
the DCs as described (25).
In some experiments, a rEBNA1 protein or rPCNA
control protein was added to the DC cell culture at the
indicated concentrations with the maturation stimu-
lus. In other experiments, 10 µg/ml of Candida albicans
cell lysate (Allermed Laboratories, San Diego, Califor-
nia, USA), mumps skin antigen USP (Pasteur Merieux
Connaught, Swiftwater, Pennsylvania, USA), or
tetanus toxoid (Wyeth Lederle, Philadelphia, Pennsyl-
vania, USA) was added to the wells with maturation
stimulus on day 6 of DC culture. For use as target in
51Cr-release assays, DCs were pulsed with either 1
µg/ml of rEBNA1 protein or rPCNA control before use
as targets. For positive selection of CD4+ T cells, CD14–
cells were treated with a monoclonal anti-human CD4
Ab conjugated to magnetic microbeads (Miltenyi
Biotech). T cells and DCs were used fresh or after cry-
opreservation in FCS and 5% DMSO.
Cell lines. Autologous B-lymphocyte cell lines (B-LCLs)
were generated on all lab donors by culturing CD14–
cells with the supernatant of the B95-8 marmoset cell
line in RPMI-1640 fortified with 20% FCS plus gen-
tamicin, glutamine, and 1 µg/ml cyclosporine A. Estab-
lished B-LCLs were then maintained in RPMI-1640 plus
10% FCS plus gentamicin and glutamine. T2 cells
(American Type Culture Collection, Manassas, Virginia,
USA) were cultured in DMEM plus 10% FCS with gen-
tamicin and glutamine.
DC infection with recombinant vaccinia viruses. Viruses
were kindly provided by M. Kurilla as described else-
where (5). Mature DCs were infected with recombi-
nant vaccinia vectors (vvTK–) as a negative control or
vaccinia vectors expressing EBNA1 deleted of the gly-
ala repeat domain (vvEBNA1∆GA) at an MOI of two
for 1 hour at 37°C, and washed three times in medi-
um with 5% human serum. Vaccinia infection was ver-
ified at 6–12 hours by intracellular staining as
described previously (26) using VV1-6B6 Ab to a vac-
cinia early protein, followed by FACS analysis. Infec-
tion of DCs was 40–60%.
Expression and purification of recombinant EBNA1 and pro-
liferating cell nuclear antigen control protein. EBNA1458–641
inserted in the expression vector pET15b (Novagen,
Madison, Wisconsin, USA) was a gift from Dan Zhang
and Michael O’Donnell (Rockefeller University, New
York, New York, USA). The vector was transfected into
Escherichia coli BL21 (DE3) pLysS cells. Proliferating cell
nuclear antigen (PCNA) expressing E. coli BL21 (DE3)
pLysS cells were a gift from Ming Guo (Weill Medical
College of Cornell University, New York, New York,
USA). Bacterial cultures were grown to an OD595 of 0.8
at 37°C. Then EBNA1 or proliferating cell nuclear anti-
gen (PCNA) expression was induced with 1 mM IPTG
(GIBCO-BRL, Grand Island, New York, USA) for 3
hours. After harvesting by centrifugation, the cells were
resuspended in 50 mM NaH2PO4, 300 mM NaCl, and10
mM imidazole to a volume of 5 ml/g of cell pellet.
Lysozyme was added to 1 mg/ml for 30 minutes on ice,
and the suspension was sonicated for complete lysis.
After centrifugation at 20,000 g for 30 minutes at 4°C,
the cleared supernatant was filtered through a 0.45-µm
filter and 1 ml of Ni-NTA agarose (QIAGEN Inc., Valen-
cio, California, USA) per 10 ml lysate was added. The
suspension was rotated for 1 hour at 4°C and packed
into a column (Bio-Rad Laboratories Inc., Hercules, Cal-
ifornia, USA). The matrix was washed with 50 mM
NaH2PO4, 300 mM NaCl, and 20 mM imidazole until
the flow through OD280 was less than 0.01. The recom-
binant proteins were then eluted with 50 mM NaH2PO4,
300 mM NaCl, and 250 mM imidazole. Protein-con-
taining fractions were pooled and dialyzed overnight at
4°C against PBS. The protein concentration was deter-
mined at OD280, purity determined by SDS-PAGE, and
identity determined by Western blot analysis with
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EBNA1-specific Ab (MAB8173; Chemicon Internation-
al, Temecula, California, USA) or the 6xH-specific Ab
AD1.1.10 (R&D Systems).
Enzyme-linked immunospot assay for IFN-γand IL-4 secret-
ing cells. Enzyme-linked immunospot (ELISPOT) assays
were performed as described previously (26). Briefly,
96-well multiscreen plates (Millipore Corp., Bedford,
Massachusetts, USA) were coated overnight at 4°C
with 10 µg/ml of IFN-γ Ab, 1-DIK, or IL-4 Ab, 82.4
(Mabtech AB, Nacka, Sweden). Plates were blocked
with RPMI with 5% pooled human serum (PHS) 1 hour
at 37°C. T cells (105 per well) were stimulated in dupli-
cate or triplicate with 3,000 DCs for 18 hours. To devel-
op the ELISPOTs, the plates were treated with a second
biotinylated 7-B6-1 IFN-γor 12.1 IL-4 Ab (MABTECH),
followed by avidin-bound biotinylated horseradish per-
oxidase (HRP) (Vectastain ABC kit; Vector Laborato-
ries, Burlingame, California, USA). Spots were devel-
oped for 5 minutes in stable 3,3-diaminobenzidine
(DAB; Research Genetics, Huntsville, Alabama, USA),
washed with sterile water, and air-dried before count-
ing using a stereomicroscope. A vvEBNA1∆GA
response was considered significant if it was ten spots
greater than the negative control (vvTK–) and at least
twice that of the negative control.
Expansion of ELISPOT-producing CD4+ T cells. Positively
selected CD4+ T cells were expanded for 7 days in medi-
um supplemented with 5% PHS, with vvEBNA1∆GA-
infected DCs or vvTK-infected DCs at a DC/T-cell ratio
of 1:30. In some experiments we added 5 µg/ml of
W6/32 anti-MHC class I or L243 anti-MHC class II
blocking Ab on days 0, 3, and 7. At day 7, expanded cells
were restimulated with DCs pulsed with 1 µg/ml
rEBNA1 or control protein, rPCNA, and assayed for
IFN-γ or IL-4 ELISPOTs. To compare the response to
EBNA1 with other antigens, 105 positively selected
CD4 lymphocytes were expanded for 7 days with DCs
alone or DCs pulsed with 10 µg/ml of C. albicans cell
lysate, tetanus toxoid, mumps skin antigen, rPCNA
control protein, or rEBNA1 protein in a 96-well plate
with a DC/T-cell ratio of 1:30. On day 7, the super-
natant was replaced with fresh media, and wells were
split 1:2, with half the well restimulated with DCs
pulsed with appropriate antigen and half the well stim-
ulated with either appropriate control antigen or DCs
pulsed with nothing and assayed for IFN-γ or IL-4
secretion by ELISPOT.
Generation of EBNA1-specific cell lines by cytokine secre-
tion in freshly stimulated PBMCs. PBMCs (75 × 106) were
stimulated with autologous vvEBNA1∆GA-infected
DCs at a ratio of 30:1 in medium fortified with 5%
PHS for either 7 hours (IFN-γ) or 18 hours (IL-4). Then
the cells were washed with MACS buffer, centrifuged
10 minutes at 1,800 rpm, and resuspended in cold
RPMI containing 10% FCS (R10) at a concentration of
107 cells per 80 µl of media. A primary anti-CD45 Ab,
conjugated to either anti–IFN-γor anti–IL-4 (Miltenyi
Biotec) was then added at a ratio of 10 µl of Ab per 107
cells. The cells were then placed on ice for 5 minutes,
then by the addition of warm R10 to a concentration
of 5 × 106 cells per milliliter, and incubated for 45 min-
utes under continuous rotation at 37°C. After this
incubation, cells were washed with MACS buffer and
centrifuged. The pellet was resuspended in 80 µl of
MACS buffer per 107 cells and 10 µl/107 cells of sec-
ondary Ab to either IFN-γ or IL-4 labeled with phyco-
erythrin (PE; Miltenyi Biotec), placed on ice for a 10
minutes, followed by washing with MACS buffer and
centrifugation. A final anti-PE Ab labeled with a para-
magnetic microbead (Miltenyi Biotec) was added at a
ratio of 10 µl/107 cells for 15 minutes at 4°C. Magnet-
ic separation was performed as above and repeated to
increase purity of the recovered cells. Cells were then
centrifuged and cultured in medium with 5% PHS and
105 irradiated CD14– feeder cells in one well of a 
96-well plate. The cells were restimulated weekly; alter-
nating vvEBNA1∆GA-infected DCs with DCs pulsed
with 2 µg/ml rEBNA1 at the time of the maturation
stimulus (days 5–7). After 3 weeks, 10 U/ml IL-2 (Lym-
phocult; Biotest, Minneapolis, Minnesota, USA) was
added. In this way, we were able to set up lines from
cells isolated from fresh blood that secreted 
IFN-γ and IL-4 in response to EBNA1-pulsed DCs.
FACS and functional analysis of IFN-γ and IL-4 cell lines.
Cells (104), 3 weeks after initiation of the lines as
above, were stained 15 minutes on ice with Simultest
(CD4 FITC and CD8 PE), or isotype controls (IgG1
FITC and IgG2a PE; PharMingen, San Diego, Califor-
nia, USA), or PE-labeled CD56 Ab, or PE-labeled iso-
type control (PharMingen) at a ratio of 1:50. After
three washes and fixation with 4% paraformaldehyde,
cells were analyzed on a FACScan (Becton Dickinson,
San Diego, California, USA). For cytotoxic activity, the
cell lines in triplicate were added to 104 targets at the
indicated effector/target ratios for 5 or 24 hours. The
targets were labeled with 50 µCi Na251CrO4 for 1 hour
at 37°C and washed three times with R10. To meas-
ure cytolysis, 50 µl of culture supernatant was added
to 100 µl of scintillation fluid (Wallac, Turku, Fin-
land) in a 96-well sample plate, and radioactivity was
measured in a gamma counter (1450 Microbeta
counter; Wallac). Percentage of specific lysis was cal-
culated by the following formula: [(cpm experimental
well – cpm spontaneous release) / (cpm total release –
cpm spontaneous release)] × 100%. Spontaneous
release was determined by incubating labeled targets
in medium alone and total release by incubating tar-
gets with 1% Triton X-100.
ELISA for IgG subclasses. Ninety-six–well polystyrene
plates (Nalgene Nunc International, Rochester, New
York, USA) were coated with 1 µg/well of rEBNA1 pro-
tein, mumps skin antigen USP (Pasteur Merieux Con-
naught), tetanus toxoid (Wyeth Lederle), C. albicans cell
lysate (Allermed Laboratories) in PBS or PBS alone
overnight at 4°C. Plates were blocked with 50 µl/well
3% nonfat milk powder for 30 minutes, followed by 30
minutes in PBS containing 3% BSA. Test plasma sam-
ples, diluted 1:10 or 1:100 in 3% BSA, were added for
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20 minutes at room temperature. Plates were washed
three times with TBST (10 mM Tris, 140 mM NaCl,
0.05% Tween 20). Biotin mouse anti-human IgG1,
IgG2, IgG3, IgG4 Ab’s (PharMingen) were added at
1:1000 in TBST for 20 minutes at room temperature.
After plates were washed three times in TBST, avidin-
bound biotinylated HRP was added for 20 minutes at
room temperature, followed by TMB substrate (R&D
Systems) to develop the reaction for 10 minutes at
room temperature and 1 M H2(SO4) to stop the reac-
tion. Plates were read in a microplate reader (Dynex
Technologies, Chantilly, Virginia, USA).
Results
CD4+ T-cell responses to EBNA1 primarily involve IFN-γTh1
cells. In a previous study (24), we identified EBNA1-
specific, IFN-γ–secreting, CD4+ T cells using two, week-
long stimulations by DCs infected with recombinant
vaccinia EBNA1 virus (vvEBNA1∆GA). Here, we
assessed if this response could be detected at the time
of T-cell isolation (day 0) and after 1 week of expansion
(day 7), and we enumerated both IFN-γ– and IL-
4–secreting cells. At both time points, no EBNA1-
dependent T cells could be detected in cultures stimu-
lated with DCs infected with control vaccinia virus
(vvTK–). With DCs expressing vvEBNA1∆GA, we
found Th1 cells in seven of 19 normal donors in day-0
cultures, but Th2 in none (P = 0.011) (Figure 1, a and
b). In 1-week cultures, 18 of 19 donors demonstrated
an expansion of IFN-γ cells, but only two of 19 had
EBNA1-dependent IL-4 secretors (P < 0.001)(Figure 1,
a and b). In these two individuals who made detectable
IL-4, the number of IFN-γELISPOTs was nevertheless
three times greater. Therefore, in most donors,
EBNA1-responsive CD4+ T cells have a Th1 phenotype,
secreting IFN-γ and not IL-4.
To verify the MHC II restriction of these CD4+
T-cell responses, we stimulated T cells with vvEB-
NA1∆GA-infected DCs for 1 week in the absence or
presence of blocking Ab’s to MHC class I (W6/32) or
HLA-DR (L243). When IFN-γ–secreting cells were
enumerated by ELISPOT, only the L243 mAb
decreased responses by a range of 88–100% in three
experiments (data not shown). We conclude that
CD4+ T-cell responses to EBNA1 are primarily MHC
II restricted and of the Th1 type.
In addition to vaccinia vectors as a source of EBNA1
protein, we tested the efficacy in an ELISPOT assay of a
purified recombinant EBNA1 protein consisting of
amino acids 458–641, with rPCNA as a control. These
proteins, checked for purity and specificity by SDS
PAGE and Western blot analysis (Figure 2a), were pulsed
in graded doses onto DCs and used to read IFN-γ
ELISPOTs after a week’s expansion with vvEBNA1∆GA-
infected DCs. Figure 2b shows the dose response of
rEBNA1 compared with rPCNA control. The inset com-
pares responses of vvEBNA1∆GA-expanded cells res-
timulated with vvTK– or vvEBNA1∆GA. A dose of only
1 µg/ml of rEBNA1 protein pulsed onto DCs gave a
response that was comparable to that of the recombi-
nant vaccinia EBNA1. This result demonstrates that
EBNA1-specific Th1 cells are capable of responding to
very low doses of EBNA1.
EBNA1-specific, cytokine-secreting cells isolated directly ex
vivo are primarily CD4+. Since the EBNA1-specific
ELISPOT responses from most donors required a
week’s culture of CD4+ T cells with DCs, which make
high levels of the Th1-skewing cytokine IL-12 (27, 28),
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Figure 1
EBNA1-specific T-cell responses are dominat-
ed by Th1-cytokine secretion. CD4+ T cells were
stimulated with DCs infected with
vvEBNA1∆GA or vvTK– (negative control) and
tested for their secretion of IFN-γ (a) or IL-4 (b)
on the day of T-cell isolation (day 0) and after
1-week expansion (day 7). Values shown are
the mean of triplicates and were derived by
subtracting the negative control from the num-
ber of EBNA1-specific spots. A vvEBNA1∆GA
response was considered significant if it were
at least ten spots above the vvTK– control (usu-
ally less than 20 spots) and at least twice this
negative control. SFCs, spot-forming cells.
we isolated EBNA1-specific cells directly ex vivo.
EBNA1-specific Th1 and Th2 cell lines were isolated
and expanded from six donors (see Methods).
EBNA1-specific, IFN-γ–secreting cell lines were estab-
lished in all six donors, and IL-4–secreting lines in three
of six donors. When the lines were analyzed by FACS
(for CD56, CD4, or CD8), both IFN-γ and IL-4 lines
consisted primarily of CD4+ cells. Figure 3 shows rep-
resentative IFN-γ–secreting lines from three donors
demonstrating that greater than 90% of the cells
expressed CD4 and less than 2% expressed CD8 or
CD56 (data not shown). Likewise, three EBNA1-specif-
ic, IL-4–secreting lines consisted of greater than 90%
CD4 and less than 2% CD8 or CD56 cells (data not
shown). We conclude that EBNA1-specific, cytokine-
secreting CD4+ T cells in healthy adults are already dif-
ferentiated in vivo (Figure 3), but these cells typically
must be expanded for 1 week with autologous DCs in
vitro to be detected in ELISPOT assays (Figure 1).
EBNA1-specific Th1 and not Th2 CD4 T cells are able to
lyse EBNA1-expressing DCs. We had shown previously
that EBNA1-specific T-cell lines could kill autologous
B-LCLs and DCs pulsed with different sources of
EBNA1 protein (24). We assessed if this function was
primarily expressed by Th1 lines, as has been observed
with CD4+ T cells specific for other antigens (29–31).
IFN-γ cell lines from five donors and IL-4 lines from
three donors were tested simultaneously in cytotoxic-
ity and ELISPOT assays. The cell lines maintained a
Th1 or Th2 polarity after weeks of stimulation in the
absence of exogenous IL-12 or IL-4 (Figure 4a). When
we tested lysis of vvEBNA1∆GA-infected DCs, DCs
loaded with rEBNA1 protein, or autologous B-LCL by
51Cr-release assay, only Th1 lines lysed EBNA1-express-
ing targets over the controls, though the Th2 cell lines
recognized EBNA1-expressing DCs with the secretion
of IL-4. Figure 4b shows data at graded effector/target
(E/T) ratios, while Figure 4c summarizes killing at an
E/T ratio of 10:1 for several lines. Th1 but not Th2 cell
lines had cytolytic activity.
Polarized secretion of IFN-γby expanded CD4+ T cells after
1-week culture is not seen with other microbial antigens. To
compare EBNA1 with other proteins under our stimu-
lation conditions, we cultured purified CD4+ T cells
from five donors with DCs that had been pulsed with
nothing, rEBNA1, rPCNA control protein, Candida cell
lysate, mumps skin antigen, or tetanus toxoid. Most
adults are known to be primed to these latter three
antigens. We then tested for IFN-γ and IL-4 cytokine
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Figure 2
EBNA1-specific responses can be detected at very low doses of anti-
gen. A recombinant EBNA1 protein or control PCNA protein was
eluted from E. coli–expressing vectors. Proteins were dialyzed
overnight and tested for purity with SDS PAGE (left) (a). The recov-
ered rEBNA1 protein was tested for specificity by Western blot analy-
sis using an anti-EBNA1 Ab MAB8173 (right). The Ab AD1.1.10. 
recognizes a histidine tag contained in the rEBNA1 protein. The
vvEBNA1∆GA-infected DCs were used to expand CD4+ T cells in a 
1-week culture. The expanded T cells were restimulated using DCs
pulsed with the indicated concentration of rEBNA1 protein or rPCNA
control protein and read out using ELISPOT (b). The rEBNA1 pro-
tein was added to the DCs during the maturation phase (days 6–8)
of the DC culture. The inset graph shows the ELISPOT results of
CD4+ T cells expanded with vvEBNA1∆GA-infected DCs for 1 week
and restimulated with either vvEBNA1∆GA-infected DCs or vvTK–
control. LMW, low molecular weight marker.
Figure 3
EBNA1-specific, cytokine-producing cells from fresh blood are CD4+
T cells. Freshly isolated PBMCs were stimulated with vvEBNA1∆GA-
infected DCs for either 7 hours for maximal production of IFN-γ or
18 hours for IL-4. They were then positively selected based on the
secretion of either IFN-γ or IL-4. IFN-γ cell lines were established in
six of six donors and IL-4 cell lines in three of six donors. Shown here
are CD4 versus CD8 stains of three IFN-γ lines analyzed by FACS.
Gates were set on the lymphocyte population and on living cells as
determined by propidium iodide staining.
secretion with ELISPOT at day 0 and day 7. In 1-day
cultures, two of five donors demonstrated a significant
EBNA1-specific IFN-γresponse, but no donor demon-
strated IL-4 secretion (Figure 5a). One of five donors
responded to mumps and tetanus toxoid with the
secretion of IFN-γ, but in contrast to EBNA1, three of
five donors had IL-4–secreting antigen-specific T cells
to Candida and mumps. IL-4 secretion was also detect-
ed on day 0 for two of five donors in response to stim-
ulation with tetanus toxoid. In 7-day cultures, all five
donors expanded IFN-γ–secreting EBNA1-specific 
T cells, but none had IL-4–positive ELISPOT results
(Figure 5b). In contrast, an expansion of IL-4–secreting
T cells specific for Candida and tetanus toxoid in 1-week
culture was seen in all donors. Expansions of IFN-
γ–secreting cells were also seen in some donors. For
these other antigens, the presence of IFN-γ–secreting
Th1 cells in culture did not prohibit simultaneous
growth of IL-4–secreting cells. Furthermore, the use of
DCs as antigen-presenting cells did not polarize to Th1
in the control antigens. The polarized Th1 response
seen for EBNA1 in 1-week cultures was therefore dis-
tinct among the microbial antigens tested.
EBNA1-specific IgG subclasses in vivo reflect Th1 immuni-
ty. To assess the relative activity of EBNA1-specific Th1
and Th2 cells in vivo, we monitored the IgG subclass of
the Ab response. In humans, it is believed that Th1
cytokines skew Ab responses toward the IgG1 opsonic
and complement-fixing subclass and Th2 toward the
allergic IgG4 subclass (32–34). However, the data are
based on observations of IgG subclass in the context of
disease states thought to be Th1 mediated, such as
Lyme borreliosis and tuberculoid leprosy. An ELISA
assay for IgG subclasses was used to describe the iso-
type of EBNA1-specific IgG Ab’s and Ab’s to other anti-
gens. In all 20 donors tested, EBNA1-specific IgG1 Ab’s
were more abundant than all other IgG subclasses (Fig-
ure 6a; P < 0.001). In addition, the mean OD for
EBNA1-specific IgG1 was significantly higher than the
mean OD for all the other antigen-specific IgG1
responses (P < 0.0001 for all antigens). The Ab data,
coupled with the ready detection of IFN-γ–secreting 
T cells in fresh and 1-week cultures of CD4+ T cells,
indicates that the response to EBNA1 in vivo in healthy
EBV carriers is consistently Th1 in type.
Discussion
How might the EBNA1-specific CD4+ T-cell response be skewed
toward Th1 in vivo? The new data in this study indicate
that healthy EBV carriers consistently make a Th1-type
response to EBNA1 in vivo. These cells can be expanded
directly from blood and likely explain the observed skew-
ing of the anti-EBNA1 Ab response to the IgG1 isotype.
Since B cells and B-cell lines are not known to actively
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Figure 4
EBNA1-specific Th1 cells, but not Th2 cells, lyse EBNA1-
expressing DCs. Cell lines were isolated from PBMCs stimulat-
ed with vvEBNA1∆GA-infected DCs for either 7 hours (IFN-γ)
or 18 hours (IL-4). The cells were then positively selected based
on the secretion of IFN-γ or IL-4. EBNA1-specific IFN-γ– and IL-
4–producing cells were isolated from six of six donors and three
of six donors, respectively. These cells were expanded with
weekly restimulations of irradiated vvEBNA1∆GA-infected DCs
alternating with DCs pulsed with a rEBNA1 protein. (a) Cells
were restimulated with vvEBNA1∆GA-infected or vvTK–-infect-
ed DCs and tested for either IFN-γ or IL-4 secretion after 3
weeks of expansion. The IFN-γ–secreting cell line isolated from
donor 3 representative of all Th1 cell lines is shown in the left
panel, and a representative EBNA1-specific IL-4–secreting cell
line from donor 1 is illustrated in the right panel. (b) Cells were
then tested for their ability to lyse vvEBNA1∆GA-infected DCs
by 51Cr-release assay. The results of the 51Cr release from cell
line from donor 3 are shown with graded effector-to-target
ratios and are representative of all six established IFN-γ cell
lines (left panel). Results shown are from a cell line established
from donor 1 and are representative of all IL-4–secreting cell
lines isolated. (c) CTL assay results at an effector-to-target ratio
of 10:1 are shown for five IFN-γ cell lines and three IL-4 lines
for three sources of EBNA1 antigen (vvEBNA1∆GA, rEBNA1,
or the physiologically expressed protein in B-LCL) as compared
with controls (vvTK, rPCNA control protein, or T2 cells, respec-
tively). Different symbols are representative of each cell line,
with Th1 cell lines as open symbols and Th2 cell lines as filled
symbols. Th1 and Th2 cell lines isolated from the same donor
share symbol shapes.
produce IL-12 or to bias the CD4+ T-cell response toward
Th1, we suspect that DCs, which are high IL-12 produc-
ers (27, 28), are responsible for Th1 skewing. It is now
known that human DCs efficiently cross-present
EBNA1 from dying EBV-infected B cells (24) and that
mouse DCs skew T cells toward the Th1 type in vivo (35,
36). Perhaps this cross-priming occurs during acute
infection when there is death of B cells undergoing lytic
infection with EBV. Therefore, we would suggest that
DCs, rather than infected B cells, are the direct inducers
of the Th1 response to EBNA1 in healthy carriers.
The importance of CD4+ T cells in resistance to persistent
viral infections. In HIV-1 infection, a minority of patients
have high CD4+ T-cell counts and low viral loads with-
out antiretroviral therapy (37). These long-term non-
progressors are distinct in their vigorous CD4+ T-cell
proliferative responses to HIV p24 and gp160 protein.
The role of CD4+ T cells in chronic viral infection has
been more directly assessed in mice (16). Primary infec-
tion with the murine γ-herpesvirus, MHV-68, resolves
similarly in MHC class II–/– and MHC class II+/+ mice.
However, 3 weeks after the initial infection, the virus
recrudesces in MHC II knock-out mice, which then
develop wasting, and within 4 months the majority die.
This occurs despite the fact that initial viral clearance
takes place, apparently through CD8+ T-cell cytotoxic-
ity (16). Taken together, these results are part of an
emerging consensus that CD4+ T cells maintain effec-
tive CD8+ T-cell function against viruses (reviewed in
ref. 14) and tumors (reviewed in ref. 13).
The mechanism underlying this role for CD4+ T cells
could reflect improved function of antigen-presenting
cells, especially DCs (17, 19, 20). CD40L, which is
expressed more abundantly on activated CD4+ than
CD8+ T cells, is strongly implicated as the stimulus for
DCs. CD40 is abundant on DCs, and its ligation medi-
ates several critical steps in DC development and func-
tion. This includes their generation from CD34+ pro-
genitors (38), mobilization from peripheral tissues
(39), maturation (40), survival (41), and cytokine secre-
tion, particularly IL-12 (27, 28).
The Th1 subset of CD4+ T cells is more important than Th2
in resistance to viruses and tumors. Cytomegalovirus-
seronegative (CMV-seronegative) recipients of CMV-
positive kidneys were monitored for CMV-specific
immune responses after transplantation and a polar-
ized Th1 response was observed (42). These patients
recovered from acute infection without signs of
chronic CMV disease, despite immunosuppressive
therapy. Mouse models more directly illustrate the
importance of Th1 CD4+ cells in immunological
resistance to persistent antigens. When ovalbumin
was expressed in tumors as a surrogate antigen, adop-
tive transfer of ovalbumin-specific Th1 cells led to
stronger CD8+ T-cell memory than adoptive transfer
of Th2 cells with the identical T-cell receptor for oval-
bumin (31). In another study, neonatal mice immu-
nized with an influenza subunit vaccine, in combi-
nation with IL-12, exhibited enhanced Th1 cytokine
expression and demonstrated a 100% survival after
challenge with influenza virus in comparison with a
55% survival rate among neonatal mice immunized
with influenza subunit vaccine alone (43). A recent
study employed adoptive transfer of Th1 and Th2
cells expressing an identical TCR transgene specific
for the vesicular stomatitis virus (VSV) glycoprotein
into TCRβ–/–δ–/– mice (44). Both Th1 and Th2 T cells
conferred systemic protection against VSV infection,
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Figure 5
IFN-γ–secreting cells dominate the
response to EBNA1, but not other anti-
gens. Positively selected CD4+ T cells
(105) were stimulated with 3,000 DCs
pulsed with 10 µg/ml of rEBNA1 protein,
mumps skin antigen, candidal cell lysate,
or tetanus toxoid. IFN-γ and IL-4 secre-
tion was measured on the day of T-cell
isolation (a) and after 7-day expansion
(b). CD4+ T cells stimulated with
unpulsed DCs served as a negative con-
trol for control antigens, and rPCNA-
pulsed DCs served as a control for
rEBNA1. Results shown have the negative
controls subtracted from the total. Con-
trol wells containing T cells stimulated
with unpulsed DCs and rPCNA DCs had
0–30 spots. Results were considered pos-
itive if there were more than ten spots
and twice that of the negative control.
most likely through the elaboration
of neutralizing anti-envelope Ab’s.
However, when the mice were chal-
lenged with a vaccinia-VSV recombi-
nant virus, only Th1 CD4+ T cells to
VSV glycoprotein protected the mice
against the recombinant virus. Fur-
thermore, only the Th1 cells provoked a delayed-type
hypersensitivity (DTH) response and protected
against lethal intranasal infection.
Several possible mechanisms for the protective function of
Th1 CD4+ T cells. Th1 CD4+ T cells could control viral
infections through cytotoxicity. In the current study,
only Th1 cells could lyse EBNA1-expressing targets
(Figure 4). The restriction of cytotoxicity to Th1 cells
has been described previously (29–31). Likewise, in a
model in which ovalbumin-specific Th1 and Th2
cells were generated from TCR-transgenic mice and
tested for their ability to lyse murine tumor cells
expressing ovalbumin, only the IFN-γ–secreting CD4+
T cells lysed tumor cells (31).
Th1 and Th2 cells also differ in their ability to
home to sites of infection (45, 46). Th1 cells, but not
Th2 cells, migrate in response to the chemokines,
MCP-1, Mig, and IP-10, which are produced in infect-
ed tissues (44). This is due to differential expression
of chemokine receptors, Th1 cells expressing CCR2
and CXCR3 and Th2 cells, CCR3 and CCR4.
As mentioned above, in a murine model of tumor
immunity, adoptive transfer of either Th1 or Th2 cells
eradicated tumors, but the mechanisms of tumor
eradication appeared very different between the two
types of helper cells. In mice receiving Th1 cells, the
tumor was infiltrated mainly by lymphocytes. Con-
versely, the mice that received Th2 cells demonstrated
a tumor infiltrate marked by eosinophils and neu-
trophils. Interestingly, only Th1 cells generated
immunological memory to tumor rechallenge (31).
Perhaps Th1 cells are better able to induce IL-15, a
known product of DCs (47, 48) and a key factor in
maintaining CD8+ T-cell memory (49).
The isotype of IgG Ab’s to microbial antigens. In mice, IgG
subclass switching is strongly influenced by the type
of T-helper cytokines secreted (reviewed in ref. 50).
IFN-γ selects for IgG2a Ab’s and IL-4 switches the
response toward allergic IgG1 and IgE isotypes. In
humans, increased levels of IL-4 direct secretion of
IgG4 (51, 52), while certain disease states that are
thought to be Th1 mediated show an increase in either
IgG1 (32, 34, 53, 54) or an elevated IgG2/IgG3 ratio
(55). However, these studies have not correlated the
IgG subclass of human Ab’s with cytokine secretion of
the antigen-specific T-helper cells.
The current study compares Ab isotypes and T-cell
cytokine secretion for several microbial antigens
(Figures 5 and 6). EBNA1-specific Ab was primarily
of the IgG1 type, and this correlated with a consis-
tently polarized IFN-γ secretion by EBNA1-specific
T cells. The other microbial antigens elicited secre-
tion of both IL-4 and IFN-γ from CD4+ lymphocytes,
and the IgG Ab’s to these antigens were distributed
across the different subclasses.
Elevations of IgG1 have been reported for other
chronic viral infections, such as hepatitis B (53, 56)
and CMV (54). The ability of IgG1 immunoglobulins
to fix complement and bind to macrophage Fc recep-
tors is thought to be important in the neutralization
of free viral particles (57). We conclude that the
observed polarization of EBNA1-specific IgG sub-
classes is most likely a consequence of a predominant
Th1 phenotype of responding CD4+ lymphocytes and
provides evidence for the polarization of the T-cell
response to Th1 in vivo.
Implications. Since the CD8+ T-cell arm of the EBNA1
response is blocked at the level of antigen presentation
on MHC class I, the CD4+ response becomes the prin-
cipal T-cell mechanism to recognize EBNA1, which is
the sole latency antigen known to be expressed in all
forms of EBV-associated cancers. Because the EBNA1
response is of the Th1 type that conveys resistance to
viruses and tumors, this protein provides a new focus
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Figure 6
EBNA1-specific Ab’s are predominantly IgG1 in
contrast to Ab’s to three other microbial anti-
gens. Values shown are the mean of 20 donors
with the plasma diluted 1:10 with 3% BSA. The
background levels in the absence of antigen for
each IgG subclass were subtracted from the
results with the microbial proteins. IgG subclass
distribution of Ab’s specific to a rEBNA1 protein
are shown (a). IgG subclass distribution to other
proteins, mumps, Candida, and tetanus toxoid
were also determined (b–d).
for vaccination and immunotherapy. Reciprocally, a
loss of the Th1 phenotype of the EBNA1 response may
allow for the development of EBV-associated malig-
nancies. It will be important to determine if both the
quality and quantity of EBNA1 immunity is altered in
these conditions. It is known that Reed-Sternberg cells
in Hodgkin’s lymphoma make large amounts of IL-13
(58). Like IL-4, IL-13 can skew the CD4 response to the
Th2 type, thereby reducing T cell–mediated resistance,
as suggested by the literature, to other persistent virus-
es and tumors discussed above. We would suggest that
vaccines and therapies against EBV and EBV-associat-
ed malignancies should include a means to elicit a
polarized Th1 CD4+ response to EBNA1, most likely by
targeting EBNA1 to mature immunogenic DCs.
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